Russian Medical Inquiry
(RMZh. Meditsinskoe Obozrenie) ISSN 2587-6821 (Print), 2686-9918 (Online)

VAK

Scopus

E-libraryDimensions

russian citation indexULRICHS

roaddoaj

CyberleninkaGoogle Scholar

vinitiResearch4life

MendeleyScilit

РГБWhite list




Open accessCrossrefAntiplagiat

RMJ.ru




Effectiveness of synbiotics in children with atopic dermatitis
T.G. Malanicheva, N.V. Ziatdinova, I.N. Serdinskaya

Kazan State Medical University

Aim: to improve methods of atopic dermatitis (AD) treatment in children on a basis of Maxilac® Baby synbiotic effectiveness study in children of the first years of life as part of complex therapy of this pathology.
Patients and Methods: 65 children with AD at the age from 4 months to 2 years, who are divided into two groups, were examined. A main group consists of 35 children receiving Maxilac® Baby synbiotic as a part of the complex therapy 1 sachet per day for 20 days. A comparison group — 30 children receiving only traditional antiallergic therapy, which in the compared groups did not differ. Clinical examination methods were performed with an assessment of AD severity on a SCORAD scale, as well as laboratory-instrumental and specific allergological methods.
Results: Against the background of ongoing therapy in children of the main group, overall therapeutic effect was 91.4±5.1%, and in the comparison group — 80.0±4.3%, p <0.05. This was manifested by a reduction of exacerbation period by 1.5 times — from 13.8±1.4 to 9.1±2.3 days, p <0.05. A high individual therapeutic effect (HIE) was observed by 2 times more often in the main group of children, and a low HIE was by 2.3 times less frequent than in the comparison group. In the main group of children, the SCORAD index decreased by 5 times — from 29.0±4.8 to 5.6±1.8, and in the comparison group by 3 times — from 29.3±4.7 to 9.8±1,9 points, p <0.05. Long-term positive effects were characterized by a prolongation of remission by 3 times, and in 62.8% of patients in the main group there was stable remission during an observation period against the background of a 3-fold decrease in a total IgE level and more than 1 class decrease of allergen-specific IgE level, as well as normalization of intestinal microbiota.
Conclusion: the obtained results open new possibilities for using Maxilac® Baby synbiotic in children with AD.

Key words: atopic dermatitis, food allergy, children, complex therapy, microbiota, synbiotic, Maxilac® Baby.
For citation: Malanicheva T.G., Ziatdinova N.V., Serdinskaya I.N. Effectiveness of synbiotics in children with atopic dermatitis // RMJ. 2018. № 9. P. 69–72.

License Creative Commons
This work is licensed under a Creative Commons «Attribution» 4.0 License.


Previous article
Next article